Dentin Bridge Formation After Indirect Pulp Capping With Bioactive Glass Incorporated in Resin Composite and Its Adhesive in Comparison With Light Cured Calcium Hydroxide

Sponsor
Al-Azhar University (Other)
Overall Status
Completed
CT.gov ID
NCT04274920
Collaborator
(none)
36
1
2
16
2.3

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the effect of application of bioactive glass in different protocols on the formation of dentin bridge after indirect pulp capping using resin composite with its adhesive both are containing bioactive glass.

Condition or Disease Intervention/Treatment Phase
  • Other: Bioactive Glass
  • Other: Light cured calcium hydroxide
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Clinical Response of Human Pulps Capped With Bioactive Glass Incorporated in Resin Composite and Adhesive
Actual Study Start Date :
Mar 1, 2017
Actual Primary Completion Date :
May 1, 2018
Actual Study Completion Date :
Jul 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bioactive Glass

18 teeth were capped indirectly with dental adhesive containing bioactive glass applied according to the manufacturer's instructions and cured for 20 seconds and then resin composite restoration containing bioactive glass applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.

Other: Bioactive Glass
Bioactive glass was incorporated in resin composite and its adhesive

Active Comparator: Light cured calcium hydroxide

18 teeth were capped indirectly with light cured calcium hydroxide (control group) applied according to the manufacturer's instructions by calcium hydroxide applicator and light cured for 20 seconds then resin composite restoration was applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.

Other: Light cured calcium hydroxide
Light cured calcium hydroxide

Outcome Measures

Primary Outcome Measures

  1. Change of dentine thickness [baseline, one month, 3 months and 6 months]

    Thickness in millimeters using CBCT

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 35 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Active carious lesion in deep dentin of molars.

  • Absence of cavitated lesions at the buccal or lingual surfaces as determined by clinical and radiographic examination.

  • Absence of clinical diagnosis of pulp exposure, fistula, swelling of periodontal tissues, and abnormal tooth mobility;

  • Absence of clinical symptoms of irreversible pulpitis, such as spontaneous pain or sensitivity to pressure;

  • The extension of the carious lesion should be such that complete caries removal would risk pulp exposure, as determined by clinical and radiographic assessment;

  • Absence of radiolucencies at the interradicular or periapical regions, or thickening of the periodontal spaces, that would indicate the presence of irreversible pulp pathologies or necrosis;

  • Absence of internal or external root resorption.

  • Co-operative patients approving the trial.

Exclusion Criteria:
  • Patients with systemic medical conditions

  • pregnant females

  • Teeth with spontaneous pain or sensitivity to percussion.

  • Teeth with periodontal lesions, internal or external root resorption, mobility of tooth, sinus opening, or abscessed tooth.

  • Radiographic examination revealed, interrupted or broken lamina dura, widened periodontal ligament space, periapical radiolucency.

Contacts and Locations

Locations

Site City State Country Postal Code
1 AlAzhar University, Faculty of Dentistry for Girls Cairo Egypt

Sponsors and Collaborators

  • Al-Azhar University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Heba Arafa Abd El wahab Zahran, Principal Investigator, Al-Azhar University
ClinicalTrials.gov Identifier:
NCT04274920
Other Study ID Numbers:
  • REC16-071
First Posted:
Feb 18, 2020
Last Update Posted:
Feb 18, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 18, 2020